Clinical trials: Sadness
Seasonal Affective Disorder
Bright Light Therapy in Seasonal Affective Disorder (SAD)
The aim of this study is to investigate the efficacy of bright light therapy in SAD. This is a placebo-controlled, double-blind randomized controlled trial (RCT).
- Trial name
- VAHAVA (NCT01030276)
- Testing
- Bright light therapy
- Where
- Finland
- Volunteers
- 60 people
- Sponsor
- University of Oulu
Urinary Tract Infections
Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.
This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled, first time in human (FTIH) study, that includes both single-ascending and multiple-ascending dose phase to assess the safety…
- Trial name
- NCT04488770
- Testing
- GSK3882347
- Where
- United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
QG101-23-0 Capsules SAD and MAD Study in Healthy Subjects
The study will consist of three parts: a single-dose ascending (SAD) phase (Part A) enrolling a total of five ~ six cohorts of healthy participants, a multiple-dose ascending (MAD) phase (Part B) enrolling 3 cohorts of healthy…
- Trial name
- NCT05650528
- Testing
- QG101-23-0 capsules
- Where
- Australia
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Amckaus PTY LTD.
Healthy
Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants
The current study is the second clinical administration with PF-07304814, the phosphate prodrug of the active moiety PF-00835231, and the first in healthy adult participants.
- Trial name
- NCT04627532
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pregnancy Related, Postpartum Sadness
Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women
The postpartum period is a critical time for both maternal and child health, and more than half of all maternal deaths occur postpartum, from one day to one year after birth.
- Trial name
- NCT04475718
- Testing
- Fourth Trimester Mobile Tool
- Where
- 2 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Carelon Research
Healthy Volunteers
A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants
The purpose of this study is to evaluate the safety and pharmacokinetics of single-ascending doses of ZB004.
- Trial name
- NCT05794516
- Testing
- ZB004
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Zenas BioPharma (USA), LLC
Healthy
Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants
The study will evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamics (PD), and explore the food effect of M5049 in healthy male and female participants.
- Trial name
- NCT03676322
- Testing
- M5049
- Where
- Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Sickle Cell Disease
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.
- Trial name
- NCT05036512
- Testing
- GBT021601
- Where
- 4 sites in United States, Australia
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Pfizer
Normal Healthy Adults
A Research Study to Evaluate BLX-0871 in Healthy Adults
This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance.
- Trial name
- NCT07140081
- Testing
- BLX-0871
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Social Anxiety Disorder
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in…
- Trial name
- PALISADE-3 (NCT06358651)
- Testing
- Fasedienol Nasal Spray
- Where
- 24 sites in United States
- Volunteers
- 238 people
- Sponsor
- VistaGen Therapeutics, Inc.
Schizophrenia, Schizoaffective Disorder
Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
The major objective of this proposal is to test the hypothesis that the addition of divalproex sodium to an atypical antipsychotic drug other than clozapine will significantly improve: a) cognition; and b) psychopathology…
- Trial name
- NCT00306475
- Testing
- Divalproex Sodium Extended-Release Tablets
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Thrombosis, Cardiovascular Diseases
A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients .
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug, Vitalangio1, in healthy male and female volunteers aged 18 to 55 years old.
- Trial name
- NCT07618351
- Testing
- Experimental: Food effect group, Active Comparator: Multiple dose group
- Where
- China
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Post-Traumatic Stress Disorders, Stress Disorders
Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings
The purpose of this study is to evaluate Cognitive-behavioral therapy (CBT) for deployment-related post-traumatic stress disorder (PTSD) that can be used by behavioral health consultants working with Service Members in the…
- Conditions
- Post-Traumatic Stress Disorders, Stress Disorders, Combat Disorders
- Trial name
- NCT00974402
- Testing
- Cognitive Behavioral Therapy
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Inflammatory Bowel Disease, Colitis, Ulcerative
LMT503 First-in-human SAD, MAD, and FE Study
This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn Disease
- Trial name
- NCT05659953
- Testing
- LMT503
- Where
- Netherlands
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lmito Therapeutics Inc.
Healthy, Safety
Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers
This study aims to evaluate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of single ascending doses and multiple ascending doses of APX-115 in healthy males.
- Trial name
- NCT03694041
- Testing
- SAD: APX-115, MAD: APX-115, Food effect: fasted and fed
- Where
- France
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Aptabio Therapeutics, Inc.
OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy
SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)
A First-in-Human multi-centre, prospective, Phase1a, Single Ascending Dose (SAD) interventional study of PYC-001 in participants with confirmed OPA1 mutation (haploinsufficiency) associated ADOA.
- Conditions
- OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy, Hereditary Optic Atrophies, Kjer Optic Atrophy
- Trial name
- NCT06461286
- Testing
- PYC-001
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- PYC Therapeutics
Safety
Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts
This Phase 1 study is designed to assess the safety and tolerability of single and multiple intravenous (IV) doses of MRX-8, to assess the pharmacokinetics of MRX-8 and its primary metabolite following single and multiple IV…
- Trial name
- NCT04649541
- Testing
- MRX-8
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- MicuRx
Social Phobia
Social Anxiety Disorder Study Of Paroxetine
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).
- Trial name
- NCT00318669
- Testing
- Paroxetine hydrochloride hydrate
- Where
- 16 sites in Japan
- Volunteers
- 390 people
- Sponsor
- GlaxoSmithKline
Healthy
A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
The purpose of this First-in-Human study is to evaluate the safety , tolerability，PK and PD after single ascending of HNC664 given to healthy subjects, compared to placebo. Also, food effect will be evaluated.
- Trial name
- NCT04504448
- Testing
- HNC664 capsules Single dose, HNC664 capsules FED
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc